Get the Stockscreener App
5.29
0.57%
0.03
Annexon Inc stock is traded at $5.29, with a volume of 2.99M.
It is up +0.57% in the last 24 hours and down -4.68% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.26
Open:
$5.21
24h Volume:
2.99M
Relative Volume:
0.86
Market Cap:
$866.73M
Revenue:
-
Net Income/Loss:
$-196.48M
P/E Ratio:
-4.351
EPS:
-1.2158
Net Cash Flow:
$-183.16M
1W Performance:
-2.22%
1M Performance:
-4.68%
6M Performance:
+8.18%
1Y Performance:
+122.27%
1-Day Range:
$5.081
$5.345
1-Week Range:
$5.00
$5.505
52-Week Range:
$2.03
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.29 | 873.28M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating - Moomoo
Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance
ANNX Upgraded by Citizens -- Rating Changed to Market Perform - GuruFocus
Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp - MarketBeat
Citizens upgrades Annexon stock rating on trial endpoint changes - Investing.com
Annexon Announces $55.3 Million Net Loss in Q2 2026 Financial Results - Kalkine Media
Form 8K Annexon Inc For: 12 August By Investing.com - Investing.com Nigeria
Annexon, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Annexon (NASDAQ: ANNX) reports $99.5M H1 2026 loss and secures new $200M debt facility - Stock Titan
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Annexon Q2 2026 Earnings Call Transcript - MarketBeat
Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Annexon Releases Q2 2026 Financial Results - AlphaStreet
Investors Purchase High Volume of Call Options on Annexon (NASDAQ:ANNX) - MarketBeat
Annexon (NASDAQ:ANNX) Shares Gap Down on Disappointing Earnings - MarketBeat
Annexon Reports Q2 2026 Financials and Expands Vonaprument Phase 3 Trial in Geographic Atrophy - Kalkine Media
Earnings call transcript: Annexon misses Q2 2026 EPS view as shares fall premarket - Investing.com Nigeria
Annexon Q2 Earnings Call Highlights - MarketBeat
ANNX: Expanded pivotal trials and strong clinical results drive regulatory and financial momentum - TradingView
Annexon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Annexon Q2 Results: Net loss widens to $55.3M on higher R&D - scanx.trade
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones - Investing News Network
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts - Yahoo Finance
Annexon Expands Vonaprument Phase 3 Trial With Month 24 Dual Primary Endpoint - marketscreener.com
Why is Annexon stock sliding today? By Investing.com - Investing.com Canada
Annexon shares fall 6% on wider-than-expected quarterly loss By Investing.com - Investing.com South Africa
Annexon (Nasdaq: ANNX) deepens pipeline, adds $200M credit facility and new endpoints - Stock Titan
Annexon Q2 Loss Narrows; Shares Down Pre-Bell - marketscreener.com
Annexon shares fall 6% on wider-than-expected quarterly loss - Investing.com
Earnings Flash (ANNX) Annexon Posts Q2 Loss $0.28 a Share, vs. FactSet Est of $0.23 Loss - marketscreener.com
Annexon adds month 24 endpoint to phase 3 dry AMD trial - Investing.com India
Annexon Biosciences Q2 net loss widens, cash runway extended - TradingView
Annexon Highlights Positive Clinical Progress in GBS and GA Programs, Expands Pipeline and Extends Cash Runway Into 2028 - Quiver Quantitative
Ten Guillain-Barré patients show early strength gains in Annexon study - Stock Titan
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated ... - Enidnews.com
Annexon Expands Vonaprument Phase 3 Program in Geographic - GlobeNewswire
Dimensional Fund Advisors LP Has $5.12 Million Stake in Annexon, Inc. $ANNX - MarketBeat
Form 8K Annexon Inc For: 10 August By Investing.com - Investing.com Australia
Annexon appoints retinal surgeon Blumenkranz to board By Investing.com - Investing.com Australia
Annexon appoints retinal surgeon Blumenkranz to board - Investing.com
Annexon names Mark Blumenkranz to board as Muneer Satter steps down - Bitget
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors - The Manila Times
Annexon, Inc. Announces Board Changes - marketscreener.com
Annexon appoints retinal surgeon Mark S. Blumenkranz to board - scanx.trade
Renaissance Technologies LLC Sells 258,300 Shares of Annexon, Inc. $ANNX - MarketBeat
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Annexon Inc (ANNX) Stock News Today - tradingkey.com
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):